The effect of empagliflozin in patients with idiopathic edema

Phase 4

Recruiting

• Conditions: Idiopathic edema.; Edema, unspecified; R60.9

• Registration Number: IRCT20230314057712N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 16 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Patients over 18 years of age who refer due to generalized edema
The patient does not take drugs that cause edema
In the diagnostic investigations, there are no disorders, including kidney, heart, liver, thyroid, etc. There should be no justification and cause of generalized edema for the patient

Exclusion Criteria

Patients who do not want to cooperate and participate in the research
Patients with diseases such as advanced renal failure, liver failure, chronic or recurrent UTI
Patients with immune deficiency or diabetes
Patients who use drugs that interfere with the intervention process

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The amount of edema. Timepoint: At the beginning of the study, 2, 6 and 12 weeks after starting the mentioned drug. Method of measurement: TANITA body analysis device.

Secondary Outcome Measures

Name	Time	Method
The amount of physical activity in the International Physical Activity Questionnaire. Timepoint: before the intervention and then at the end of the second, sixth and twelfth weeks. Method of measurement: International Physical Activity Questionnaire.